Compare Apple Inc (AAPL) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Apple Inc trades at $313.3 (market cap $4.56T), while Alnylam Pharmaceuticals, Inc. trades at $323.8 (market cap $42.94B). The key difference: Apple Inc is far larger — about 106.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Apple Inc pays a 0.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| AAPL | ALNY | |
|---|---|---|
Market Cap | $4.56T | $42.94B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $491.22 |
52-Week Low | $202.38 | $278.09 |
Enterprise Value | $4.58T | $41.20B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $313.27, up 0.2% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, though valuation ratios like P/E of 37.61 are elevated. Recent news highlights AI integration via Alphabet's Gemini and ongoing retail adjustments, including store closures amid union disputes.
Outlook remains positive with analyst consensus targeting $329.62, but risks include high valuation sensitivity and competitive pressures. Earnings have consistently beaten estimates, supporting growth potential, yet investors should monitor margin pressures and regulatory scrutiny in key markets.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
